The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.

The shot is also cleared for individuals between 12 and 64 years of age who are at least one risk factor as defined by the ...

Citing concerns about mRNA technology, the Trump administration has pulled funding for a vaccine, even though Moderna says it ...

The US Food and Drug Administration has approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for individuals aged ...

After the FDA asked for more clinical data this month, Moderna has decided to resubmit the BLA later this year.

The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from ...

Moderna has withdrawn its pending application for a combination vaccine for both the flu and Covid-19, saying it will resubmit later this year once it has more data.

Moderna previously reported a summary of the results from the company-sponsored trial in 8,000 people. The mRNA technology is used in approved COVID-19 and RSV shots, but has not yet been approved ...